INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 44h ago
HOUSE PTR4h ago
SEC 13F4h ago
ROBINHOOD CHAIN4h ago
Public company

CGONCG Oncology, Inc.

CIK 0001991792

EDGAR filingsOpen in network
Disclosed transactions6
Buys / sells0 / 0
Max Insider Score24
Connections2with evidence

CGON · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
20
KA
Kuan ArthurDirector, Chief Executive Officer
CGONCG Oncology, Inc.
Option exercise
M$111K
64.6K sh
Mar 12, 2026Mar 13, 2026
traded Mar 12, 2026
+1dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2836 · Biological Products, (No Diagnostic Substances) · Nov 4, 2026
  • ← Insider ofevidence
    Kuan ArthurDirector, Chief Executive Officer · Mar 6, 2026
12
KA
Kuan ArthurDirector, Chief Executive Officer
CGONCG Oncology, Inc.
Tax withholding
F
$111K
1,847 sh
Mar 12, 2026
Mar 13, 2026
traded Mar 12, 2026
+1d
SEC FORM 4

Evidence

9
KA
Kuan ArthurDirector, Chief Executive Officer
CGONCG Oncology, Inc.
Option exercise
M—
64.6K sh
Mar 12, 2026Mar 13, 2026
traded Mar 12, 2026
+1dSEC FORM 4

Evidence

24
KA
Kuan ArthurDirector, Chief Executive Officer
CGONCG Oncology, Inc.
Option exercise
M$177K
102.9K sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC FORM 4

Evidence

12
KA
Kuan ArthurDirector, Chief Executive Officer
CGONCG Oncology, Inc.
Tax withholding
F$177K
2,871 sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC FORM 4

Evidence

9
KA
Kuan ArthurDirector, Chief Executive Officer
CGONCG Oncology, Inc.
Option exercise
M—
102.9K sh
Mar 4, 2026Mar 6, 2026
traded Mar 4, 2026
+2dSEC FORM 4

Evidence